anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Nonimmune hydrops (NIH) and severe symmetrical intrauterine growth restriction (IUGR) represent two obstetrical circumstances that occur with relative frequency yet often escape adequate etiology assessment and diagnosis prior to and after birth. Both of these conditions have high perinatal and neonatal mortality rates. While antepartum ultrasound and amniotic fluid evaluations of fetal karyotype and viral DNA studies diagnose some etiologies for NIH and severe symmetrical IUGR, large percentages of NIH (30-40%) and IUGR (20-30%) cases are attributed to idiopathic causes. Because of this uncertainty in diagnosis, many cases are subjected to prolonged antepartum hospitalization with intensive fetal monitoring and urgent delivery by Cesarean section for non-reassuring fetal status, only to succumb to a neonatal demise in the nursery. A small percentage (1-2%) of these cases are found to be due to inborn errors of metabolism by neonatal and/or postmortem evaluation; however, when combined together, greater than 50% of NIH and IUGR cases have no identifiable etiology. Therefore, any new test that may make a diagnosis for NIH or severe symmetrical IUGR prior to delivery would be extremely important to the management of both the mother and the infant. Tandem mass spectrometry for inborn errors of metabolism may represent a new tool for assessing, identifying, and treating currently unexplained cases of NIH and severe symmetrical IUGR.

This is a prospective pilot cohort study of all pregnancies complicated by NIH and severe symmetrical IUGR within the Pediatrix-Obstetrix network. This network encompasses several perinatal sites throughout the United States with corresponding neonatal intensive care units utilizing a computerized patient database (RDS). The objective of this study is to prospectively evaluate amniotic fluid of pregnancies complicated by NIH and severe symmetrical IUGR by a method called tandem mass spectrometry for inborn errors of metabolism.
Those presenting to the Emergency Department with mental ill health, substance misuse or in crisis have a worse patient journey than those presenting with physical issues alone. They wait twice as long to be seen1 and have poorer experiences. Recognising this, the RCEM/James Lind Alliance Priority Setting Partnership has placed mental health at the top of the Emergency Medicine research agenda. The question asked is: "How can care for mental health patients be optimised, whether presenting with either/both physical and mental health needs; including appropriate space to see patients, staff training, early recognition of symptoms, prioritisation, and patient experience?" An explicit research agenda has yet to emerge from this very broad question. At the most basic level, the patient population needs to be defined, the scale of the problem quantified, and current practice patterns and variation described in detail.

It has been estimated that the proportion of ED attendances related to "mental health disorders" is 4%. However these estimates are derived from retrospective data and are dependent on accurate diagnosis coding. There is a lack of data on dual diagnoses, which Scotland's Mental Health strategy has outlined as a key area for action, recommending opportunities to "pilot improved arrangements for dual diagnosis for people with problem substance use and mental health diagnosis". A literature review aiming to build a 'Typology' of psychiatric emergency services in the UK emphasised wide variation in provision and heterogeneity of models. No prospective study has yet quantified this variation in terms of waiting times, types of assessment offered, disposition and outcomes. The success of other large observational studies on ED presentations such as syncope, acute aortic syndromes and frailty suggests that a similar methodology could be applied to mental health and related presentations.
<P>PROBLEM TO BE SOLVED: To provide a factor promoting neovascularization, especially a factor promoting the wandering of endothelial cell.  <P>SOLUTION: The factor is a compound having the following properties(a) to (f), being useful as a neovascularization promoter or as a target molecule against a neovascularization inhibitor: (a) Being obtained by culturing HeLa cell in an EBM(-) medium at 37°C for 1-2 day, and found in the resultant culture supernatant. (b) Significantly promoting the wandering of normal human umbilical cord venous endothelial cell in chemotaxel assay. (c) Substantially promoting no proliferation of normal human umbilical cord venous endothelial cell. (d) Having a molecular weight of 10,000 or less. (e) Causing no substantial own deactivation by incubation at 60°C for 20 min. (f) Causing no substantial own deactivation when incubated at 37°C for 2 h in the presence of trypsin.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Oral hygiene control and mouthwash with chlorhexidine 0.12%, from the first to the last day of administration of the chemo or radiotherapy treatment. On the first day the professional will demonstrate the care. On the other days the care will be taken by the patient himself, for at least three times a day.
The DPP recommends that participants set a weight loss reduction goal of 7% or more of their baseline body weight, reduce consumption of high fat foods as a means to reduce caloric intake, and engage in brisk walking or other moderate intensity physical activity for 150 minutes per week. Sessions include information on changing energy intake and energy output through diet and exercise, and addressing psychological, social, environmental, and motivational challenges to health behavior change.
A functional microbially fermented tea extract containing a novel polyphenol derivative and a method for producing the same are provided. A functional microbially fermented tea extract containing various extracts and a novel polyphenol derivative is produced by subjecting, to an extraction treatment, a microbially fermented tea leaf obtained by culturing one species selected from  Aspergillus  sp. (PK-1),  Aspergillus oryzae  (NBRS 4214) sp. (AO-1),  Aspergillus awamori  (NBRS 4122) sp. (SK-1), and  Eurotium  sp. (KA-1) with a tea leaf. Furthermore, for example, a functional fermented tea extract enriched with a novel polyphenol derivative is produced.
OBJECTIVE: It was targeted to assess the efficacy of certolizumab on pancreas and target organs via biochemical parameters and histopathologic scores in experimental acute pancreatitis (AP).
MATERIALS AND METHODS: Forty male Sprague Dawley rats were divided into the following 5 equal groups: group 1 (sham group), group 2 (AP group), group 3 (AP + low-dose certolizumab group), group 4 (AP + high-dose certolizumab group), and group 5 (placebo group). Rats in all groups were sacrificed 24 hours after the last injection and amylase, tumor necrosis factor α, transforming growth factor β, interleukin 1β, malondialdehyde, superoxide dismutase, and glutathione peroxidase levels were studied in blood samples. Histopathological investigation of both the pancreas and target organs (lungs, liver, heart, kidneys) was performed by a pathologist blind to the groups. In silico analysis were also accomplished.
RESULTS: The biochemical results in the certolizumab treatment groups were identified to be significantly favorable compared to the AP group (P < 0.001). The difference between the high-dose group (group 4) and low-dose treatment group (group 3) was found to be significant in terms of biochemical parameters and histopathological scores (P < 0.001). In terms of the effect of certolizumab treatment on the target organs (especially on lung tissue), the differences between the low-dose treatment group (group 3) and high-dose treatment group (group 4) with the AP group (group 2) were significant.
CONCLUSIONS: Certolizumab has favorable protective effects on pancreas and target organs in AP. It may be a beneficial agent for AP treatment and may prevent target organ damage.
Lung cancer is the leading cause of cancer deaths. Advances in the systemic treatment of non-small cell lung cancer (NSCLC) have increased survival in metastatic EGFR-mutated NSCLC. However resistance to therapy can develop.

NSCLC tumors with EGFR-activating mutations are exquisitely sensitive to EGFR tyrosine kinase inhibitors with overall response rates approximating 80%. The third generation EGFR compound osimertinib is a standard first line option. Resistance to the third generation EGFR-TKI osimertinib can develop with a median PFS of 18.9 months. Current research examining acquired resistance to EGFR-TKIs has focused on overcoming these main mechanisms of EGFR-TKI resistance and understanding the impact of co-occurring alterations. Frequently altered pathways concomitantly affected with EGFR in lung cancer are cell cycle genes. This study will explore a strategy to inhibit EGFR and CDK4/6 in resistant EGFR mutated lung cancer patients post progression on osimertinib.
Guided bone regeneration (GBR) is a widely used procedure that prevents the fast in-growth of soft tissues into bone defect. Among the different types of membranes, the use of collagen membranes is the gold standard. However, these membranes are implanted in tissue location where a severe acute inflammation will occur and can be negatively affected. The aim of this study was to develop a collagen-based membrane for GBR that incorporated alginate-hydroxyapatite microparticles. Membranes were manufactured using collagen type I and gelatin and alginate-hydroxyapatite microparticles. Membranes were assessed in terms of topography by scanning electron microscopy and confocal microscopy; stability by swelling after an overnight incubation in saline and enzymatic degradation against collagenase and mechanical properties by tensile tests. Furthermore, the biological response was assessed with SaOs-2 cells and THP-1 macrophages to determine alkaline phosphatase activity and inflammatory cytokine release. Our results showed that the incorporation of different percentages of these microparticles could induce changes in the surface topography. When the biological response was analyzed, either membranes were not cytotoxic to THP-1 macrophages or to SaOs-2 cells and they did not induce the release of pro-inflammatory cytokines. However, the different surface topographies did not induce changes in the macrophage morphology and the release of pro- and anti-inflammatory cytokines, suggesting that the effect of surface roughness on macrophage behavior could be dependent on other factors such as substrate stiffness and composition. Collagen-gelatin membranes with embedded alginate-hydroxyapatite microparticles increased ALP activity, suggesting a positive effect of them on bone regeneration, remaining unaffected the release of pro- and anti-inflammatory cytokines.
Participants wear Fitbit and receive a XBOX system and the video game to strive for at least 3 50-minute medium or high intensity classes per week over 12 weeks. Participants may also take 20-minute classes or a mixture of 50- and 20-minute classes to meet the target. Participants receive resistance training as in Arm I.
The invention provides a novel crystal form for temozolomide, a method for preparing the temozolomide and a medicinal composition of the temozolomide. The novel crystal form for the temozolomide is characterized in that: Cu is used for radiation, and diffraction peaks of 2 theta represented by degrees exist at 8.2+/-0.2 and 6.0+/-0.2 in an X-ray diffraction pattern. The invention has the advantages that: a temozolomide crystal-shaped object which is suitable for industrialized production is provided; and the problems in the prior art are solved. The preparation process is simple and easy to operate, the industrialized production is convenient to operate, the quality is controllable, and the yield is stable. The crystal-shaped object obtained by the preparation process can remarkably improve the appearance and color and luster of products; the temozolomide M crystal-shaped object prepared by the method has high stability and can be stored for a long time; and in the method, the crystal-shaped object is prepared by using an organic solvent with lower toxicity, so the potential influence effect of the positioning of organic residue on human bodies is reduced to a certain degree. The advantages ensure that the invention is beneficial to the remarkable improvement on the quality of the products and is more suitable for industrialized production.
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for a computing system that identifies information about a trial program. The information is related to healthcare data for a subset of providers. The system identifies a provider based on analysis of the information and the healthcare data and provides trial program criteria for analysis at a provider system. The provider system has access to healthcare data for subjects that interact with the provider. The computing system generates data indicating a result of screening each subject by analyzing the trial program criteria against healthcare data for each subject and receives data for a selection of a subject from the provider system. The selection is determined using screening data for the subject. A referral network of the system provides the screening data for access and analysis at an investigator system.
Gambling, if done compulsively, can cause psychological, physical, social, and vocational problems. Problem gambling, or compulsive gambling, is a progressive addiction characterized by a preoccupation with gambling, a need to bet more money more frequently, restlessness or irritability when attempting to stop, and gambling more to make up for losses. This study will compare four different combinations and durations of motivational enhancement therapy (MET), cognitive behavioral therapy (CBT), and brief advice treatments for gambling versus a non-intervention condition to determine which is most effective in reducing problem gambling.

This open-label study will last a total of 9 months. Participants will be randomly assigned to one of four groups. Group 1 will have no intervention and will be instructed to call if they experience any gambling problems. Group 2 will receive 5 minutes of education on the hazards of heavy gambling. In addition, they will receive a 1-page brochure on problem gambling and its consequences. Group 3 will receive a 1-hour session of MET focused on increasing commitment to change by raising awareness of personal consequences of gambling. Group 4 will receive the same MET session as Group 3, as well as three 1-hour sessions of CBT focused on identifying specific social and mood cues associated with gambling. Treatment will end at Week 4. Participants will have two follow-up sessions held over the phone at Week 6 and again 9 months after enrollment. Gambling behavior, employment status, alcohol and drug use, psychiatric problems, and family problems will be assessed.
Systems and methods for communicating medical information. Several embodiments also include generating alerts related to medical information, which can be transmitted to different medical entities. Prescription information from a provider describing a medication prescribed for a patient can be received by a management server via the Internet. This prescription information can be communicated from the management server to a pharmacy. Shipment and delivery information is received by the management server. Administration information describing administration of the prescribed medication to a patient is received from a care facility where the medication is administered. This information is stored and accessed by the management server for many purposes, such as inventory, theft prevention, generating alerts, responding to inquiries from governmental, regulatory, and medical entities. Thus, several embodiments provide a new centralized communication point and information storage point for medical entities.
Participants allocated to the treatment group received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
OBJECTIVE: Our study was designed to explore the role of IL-37 in M1/M2 macrophage polarization imbalance in the pathogenesis of periodontitis.
BACKGROUND: Periodontitis is a chronic progressive inflammatory disease featured by gingival inflammation and alveolar bone resorption. Recent research has revealed that regulating macrophage polarization is a viable method to ameliorate periodontal inflammation. IL-37 is an anti-inflammatory cytokine, which has been reported to inhibit innate and adaptive immunity.
METHODS: For in vitro experiment, mouse macrophage RAW264.7 cells were pretreated with 0.1 ng/mL recombinant human IL-37. M1 and M2 polarizations of RAW264.7 cells were induced by 100 ng/mL LPS and 20 ng/mL IL-4, respectively. The expression of M1 (iNOS, TNF-α, and IL-6) and M2 (CD206, Arg1, and IL-10) phenotype markers in RAW264.7 cells was detected by RT-qPCR, western blotting, and immunofluorescence staining. For in vivo experiment, experimental periodontitis mouse models were established by sterile silk ligation (5-0) around the bilateral maxillary second molar of mice for 1 week. H&E staining of the maxillary alveolar bone was used to show the resorption of root cementum and dentin. Alveolar bone loss in mouse models was evaluated through micro-CT analysis. The expression of iNOS and CD206 in gingival tissues was assessed by immunohistochemistry staining. NLRP3 inflammasome activation was confirmed by western blotting.
RESULTS: IL-37 pretreatment reduced iNOS, TNF-α, and IL-6 expression in LPS-treated RAW264.7 cells but increased CD206, Arg1, and IL-10 in IL-4-treated RAW264.7 cells. LPS-induced upregulation in NLRP3, GSDMD, cleaved-IL-1β, and cleaved-caspase-1 expression was antagonized by IL-37 treatment. In addition, IL-37 administration ameliorated the resorption of root cementum and dentin in periodontitis mouse models. IL-37 prominently decreased iNOS+ cell population but increased CD206+ cell population in gingival tissues of periodontitis mice. The enhancement in NLRP3, GSDMD, cleaved-IL-1β, and cleaved-caspase-1 expression in the gingival tissues of periodontitis mice was offset by IL-37 administration.
CONCLUSION: IL-37 prevents the progression of periodontitis by suppressing NLRP3 inflammasome activation and mediating M1/M2 macrophage polarization.
Patients with advanced NSCLC with METex14del were to receive Sym015 at the RP2D. Tumors need not be MET-amplified, and patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents. mutation.
Group 4 - Recurrent or Refractory Adrenocortical Carcinoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
Levocetirizine dihydrochloride, the active component of levocetirizine dihydrochloride tablets, is an orally active H1-receptor antagonist. The chemical name is (R)-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl] ethoxy] acetic acid dihydrochloride. Levocetirizine dihydrochloride is the R enantiomer of cetirizine hydrochloride, a racemic compound with antihistaminic properties. The molecular formula of levocetirizine dihydrochloride is C21H25ClN2O3•2HCl. The molecular weight is 461.82 and the chemical structure is shown below:

Levocetirizine dihydrochloride is a white, crystalline powder and is water soluble.  
  
Levocetirizine dihydrochloride 5 mg tablets are formulated as immediate-release, white, film-coated, oval-shaped scored tablets for oral administration. The tablets are debossed with ‘S’ on one side and breakline on other side. Inactive ingredients are: anhydrous lactose, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. The film coating contains hypromellose, polyethylene glycol, polysorbate 80, and titanium dioxide.
Hypercapnic ventilation. The goal will be to maintain transcutaneous CO2 55 mm Hg (50-60 mm Hg) during the first week of life, or until extubation. A written, laminated hypercapnic ventilator algorithm will be placed at the bedside.
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) is a recently described chronic inflammatory central nervous system disease. This case report describes a young female patient presenting with weakness in bilateral upper and lower limbs and tinnitus for 2 months. A neurological examination revealed signs of brainstem and cerebellar involvement. MRI brain showed characteristic features of CLIPPERS, with punctate and nodular enhancement in the pons and cerebellum. Differential diagnoses were systematically considered and excluded. The patient showed significant clinical and radiological improvement with steroid therapy. No clinical or radiological red flags occurred during the follow-up. This case underscores the critical role of integrating clinical and radiological findings to effectively diagnose and manage CLIPPERS. It emphasises the importance of ruling out alternative diagnoses through a thorough evaluation.
We will pilot the BUD app in 19 intervention corner stores over an 8-month period in East Baltimore. During this time, we will collect data from corner store owners, producers, whole salers, and consumers.
A dental CAD/CAM application generates a 3D model representing a patient's dental anatomy. This model may be a 3D surface. The surface may also be textured with either a monochrome or color image superimposed. The display routine that is used to display the 3D model is enhanced to adjust the contrast in the region of a displayed mouse pointer (or other input device) as a user explores the display image. When this feature is activated and the mouse pointer positioned, preferably the texturing on the 3D model is recomputed in that local area and redisplayed showing greater contrast and detail. Preferably, the contrast is increased from a center to an edge of the area of contrast. Having the texturing of the model being improved and highlighted around the margin is desirable, as it allows the user to see more easily where the margin is located.
PURPOSE:The titled growth agent for promoting health, containing a plant growth hormone, a lipid capable of forming a molecular layer film in water, and a sterol. CONSTITUTION:A growth agent for animal containing a plant growth hormone (e.g., oxyauxin such as oxyindoleacetic acid, auxinthioacetic acid, gibberellin, etc.), a lipid capable of forming a molecular layer film in water (e.g., phospholipid such as phosphatidylcholine, etc., 7-dehydrocholesterol, glycolipid, etc.), and a sterol (e.g., beta-cytosterol as plant sterol, ergosterol as animal sterol, soybean oil), to give a growth agent for animal. In order to prevent decomposition plant growth hormone, flavonoid and polyphenolic acid are simultaneously added to liposome to enhance further the effect. In order to improve stability of liposome, Ca<2+> may be added to it, and in order to improve absorption properties, liposome is subjected to ultrasonic vibration to effectively miniaturize particles.